Helius Medical Technologies, Inc. (HSDT)

NASDAQ: HSDT · IEX Real-Time Price · USD
1.480
-0.040 (-2.63%)
At close: May 17, 2024, 4:00 PM
1.520
+0.040 (2.70%)
After-hours: May 17, 2024, 7:14 PM EDT
-2.63%
Market Cap 3.74M
Revenue (ttm) 668,000
Net Income (ttm) -8.87M
Shares Out 2.53M
EPS (ttm) -12.53
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 220,921
Open 1.540
Previous Close 1.520
Day's Range 1.450 - 1.571
52-Week Range 1.451 - 14.450
Beta 1.61
Analysts Strong Buy
Price Target 24.00 (+1,521.62%)
Earnings Date May 13, 2024

About HSDT

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. Heliu... [Read more]

Industry Medical Devices
Sector Healthcare
CEO Dane Carl Andreeff
Employees 22
Stock Exchange NASDAQ
Ticker Symbol HSDT
Full Company Profile

Financial Performance

In 2023, HSDT's revenue was $644,000, a decrease of -18.17% compared to the previous year's $787,000. Losses were -$8.85 million, -37.11% less than in 2022.

Financial Statements

Analyst Forecast

According to one analyst, the rating for HSDT stock is "Strong Buy" and the 12-month stock price forecast is $24.0.

Price Target
$24.0
(1,521.62% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Helius Medical Technologies, Inc. Reports First Quarter 2024 Financial Results

NEWTOWN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulatio...

5 days ago - GlobeNewsWire

Helius Medical Technologies, Inc. to Release First Quarter 2024 Financial Results on May 13, 2024

NEWTOWN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulati...

8 days ago - GlobeNewsWire

Helius Medical Technologies, Inc. Announces Pricing of $6.4 Million Public Offering

NEWTOWN, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulati...

12 days ago - GlobeNewsWire

Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center

-- Helius Medical and Shepherd Center partner on a study that aims at rehabilitating walking mobility in people recovering from stroke -- -- Shepherd Center, a top neurorehabilitation hospital, is the...

24 days ago - GlobeNewsWire

Helius Medical stock rallies 40%: explore why

Helius Medical Technologies Inc (NASDAQ: HSDT) is up close to 40% in premarket on Wednesday after teaming up with Lovell Government Services. Why is it good news for Helius Medical stock?

6 weeks ago - Invezz

Helius Medical Technologies, Inc. Announces Partnership with Lovell® Government Services to Expand Reach of PoNS Therapy™

-- Lovell is an approved supplier to the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD) -- -- Over 28,000 cases of multiple sclerosis (MS) are reported to the VA annually -- ...

6 weeks ago - GlobeNewsWire

Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results

-- Company to host call at 4:30pm today -- NEWTOWN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on ...

7 weeks ago - GlobeNewsWire

Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024

NEWTOWN, Pa., March 15, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodula...

2 months ago - GlobeNewsWire

Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke

-- Enrollment of at least ten patients at Brooks Rehabilitation will begin this month -- -- Study will evaluate the use of Portable Neuromodulation Stimulator (PoNS®) for gait and balance deficits in ...

2 months ago - GlobeNewsWire

Helius Medical Technologies, Inc. to Present at the 36th Annual ROTH Conference

NEWTOWN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulat...

2 months ago - GlobeNewsWire

Helius Medical Technologies, Inc. Secures HCPCS Codes for Portable Neuromodulation Stimulator (PoNS®) Mouthpiece and Controller

-- Significant step toward reimbursement for the only medical device approved in the U.S. for treatment of gait deficit due to multiple sclerosis (“MS”) -- -- Proceeds from recent stock issuances thro...

2 months ago - GlobeNewsWire

Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients

-- Studies uses Portable Neuromodulation Stimulator (PoNS®) to evaluate cranial-nerve non-invasive neuromodulation for gait/balance deficits in stroke patients -- -- Interaction with FDA on clinical p...

3 months ago - GlobeNewsWire

Helius Booth and Special Event at APTA Combined Sections Meeting Will Highlight Physical Therapists' Ability to Customize PoNS Therapy® to Improve Gait in People with MS

Event Appearance Caps Year of Growth: PoNS®-Trained PTs Now Found Across the United States Event Appearance Caps Year of Growth: PoNS®-Trained PTs Now Found Across the United States

3 months ago - GlobeNewsWire

Helius Medical Technologies, Inc. Announces Further Expansion of Stroke Clinical Program with the Addition of Brooks Rehabilitation Hospital

-- Brooks Rehabilitation Hospital adds a second site to the registrational program in stroke, and brings the total number of patients to 100 -- -- Study uses Portable Neuromodulation Stimulator (PoNS®...

4 months ago - GlobeNewsWire

Helius Medical Technologies to Present at NobleCon19 Annual Conference

NEWTOWN, Pa., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulati...

6 months ago - GlobeNewsWire

Helius Medical Technologies, Inc. Announces Study Results Demonstrating That PoNS Therapy™ Helps Patients with Traumatic Brain Injury Return to Work

-- Collaborative project between Pacific Blue Cross and HealthTech Connex designed to reduce long-term disability and improve quality of life for individuals suffering from traumatic brain injury (“TB...

6 months ago - GlobeNewsWire

Helius Medical Technologies, Inc. to Release Third Quarter 2023 Financial Results on November 9, 2023; Announces Extended Cash Runway into Q2 2024

-- Expects to report Q3 revenues in range of $140 - $150 thousand, reflecting the expected decrease in U.S. sales with the conclusion of the Patient Therapy Access Program (PTAP) on June 30, 2023 -- -...

7 months ago - GlobeNewsWire

Helius Medical Technologies, Inc. Receives Letter of Intent from the Québec Ministry of Health and Social Services to Purchase 30 PoNS® Devices

-- PoNS® devices to be provided to a least five sites in five separate administrative regions within Québec ---- Government-funded initiative will evaluate the benefits of PoNS Therapy™ when used by p...

7 months ago - GlobeNewsWire

Helius Medical Technologies to Participate at Two Upcoming Healthcare Conferences

NEWTOWN, Pa., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulati...

8 months ago - GlobeNewsWire

Helius Medical Technologies, Inc. Receives UPC Numbers for its PoNS® System and Mouthpiece

-- UPC numbers assigned by Wolters Kluwer Health, provider of trusted clinical technology ---- PoNS system and mouthpiece will be included in pharmacy database utilized by 17 out 20 of the top-grossin...

8 months ago - GlobeNewsWire

Helius to Bring its Innovative PoNS Therapy for Improvement of Gait in People with MS, to the 2023 Academy of Neurologic Physical Therapy Conference

Company's First-Ever ANPT Booth Sponsorship Enables Specialists to Learn More about this Breakthrough Technology on Eve of National Physical Therapy Month

8 months ago - GlobeNewsWire

University of Montreal's School of Rehabilitation to Purchase Ten PoNS® Devices for Research Study on Stroke Recovery

-- The study will evaluate the optimal time to use PoNS Therapy™ during a patient's stroke recovery journey -- -- The study will evaluate the optimal time to use PoNS Therapy™ during a patient's strok...

8 months ago - GlobeNewsWire

Helius Medical Technologies to Present at the 2023 Interdisciplinary Association of Functional Neuroscience and Rehabilitation Conference

-- Presentation to educate on Portable Neuromodulation Stimulator (PoNS®) Therapy, highlighting the differentiation from other neuromodulation technologies, and the science behind its effectiveness, c...

8 months ago - GlobeNewsWire

Helius Medical Technologies, Inc. Compliant with All Applicable Nasdaq Listing Criteria

NEWTOWN, Pa., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulat...

9 months ago - GlobeNewsWire

Helius Medical Technologies Announces Reverse Stock Split

NEWTOWN, Pa., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulati...

9 months ago - GlobeNewsWire